Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590138 | 1.00 | CYP2A6 (0.40) | CYP2A6CYP1A2CYP2C19HTR2ACNR1 | |
| SCHEMBL1440680 | 0.82 | ACP3 (0.31) | — | |
| SCHEMBL579790 | 0.82 | ACP3 (0.31) | — | |
| SCHEMBL524745 | 0.79 | CYP2A6 (0.43) | CYP2A6ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20550831 | 0.78 | IDO1 (0.38) | CES2CES1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21597319 | 0.78 | CYP2A6 (0.42) | CYP2A6ALOX5CES2CES1ALDH1A1 | |
| SCHEMBL21834675 | 0.78 | ESR1 (0.44) | CYP1A2CYP2C19ALDH1A1ALOX15MEN1 | |
| SCHEMBL191880 | 0.78 | GSK3B (0.40) | CNR1 | |
| SCHEMBL168223 | 0.78 | IDO1 (0.38) | CES2CES1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1505157 | 0.78 | TYR (0.54) | ALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015157360-A1 | PROCESSES TO MAKE PROTEIN KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-4587021-A1 | TREATING PKU WITH CORRECTORS OF MAMMALIAN SLC6A19 FUNCTION | Jnana Therapeutics Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024059005-A1 | TREATING PKU WITH CORRECTORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4274569-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004067527-A1 | THIOPHENE DERIVATIVES AS MICROBICIDES AND HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2004-08-12 | — | — | WO | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| CN-1496255-A | Inhibition of NF-KB by triterpene compositions | �������о�����չ˽������˾ | 2004-05-12 | — | — | CN | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2001060781-A2 | DIPHENYL COMPOUNDS, FORMULATIONS AND USES THEREOF | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-08-23 | — | — | WO | disclosed |
| CN-1307473-A | Triterpene compositions and methods of their use | RES DEV FOUDATION (US) | 2001-08-08 | — | — | CN | disclosed |
| EP-1104760-A1 | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CYP2A6 2951/4885CYP1A2 2089/4885CYP2C19 3145/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | CYP2A6 2951/4885CYP1A2 2089/4885CYP2C19 3145/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | CYP2A6 3100/4885CYP1A2 2383/4885CYP2C19 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.